Stock data
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO) reported revenue of US$43.77M and net income of -US$35.04M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$43.77M | — | -US$41.98M | -US$35.04M | — |
| 2024 | US$6.34M | — | -US$60.58M | -US$58.24M | — |
| 2023 | — | — | -US$79.13M | -US$76.40M | — |
| 2022 | — | — | -US$89.15M | -US$88.22M | — |
| 2021 | — | — | -US$75.04M | -US$75.80M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$18.69M | -US$6.37M | — |
| 2026-03-31 | US$12.65M | -US$9.53M | — |
| 2025-12-31 | US$13.69M | US$10.36M | — |
| 2025-09-30 | US$19.07M | -US$16.29M | — |
| 2025-06-30 | US$8.08M | -US$15.84M | — |
| 2025-03-31 | US$2.93M | -US$13.27M | — |
| 2024-12-31 | — | -US$13.09M | — |
| 2024-09-30 | US$2.26M | -US$14.02M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.